Raymond Turner

Resveratrol, a naturally occurring polyphenol that activates sirtuin 1 (SIRT1), has been shown to reduce overall levels of matrix metalloprotease‐9 (MMP‐9) in cerebrospinal fluid (CSF) samples from patients with Alzheimer's dementia (AD). Depending on the site of release, however, MMP‐9 has the potential to improve or impair cognition. In particular, its release from microglia or pericytes proximal to the blood brain barrier can damage the basement membrane, while neuronal activity‐dependent release of this protease from glutamatergic neurons can instead promote dendritic spine expansion and long‐term potentiation of synaptic plasticity. In the present study, we test the hypothesis that resveratrol reduces overall MMP‐9 levels in CSF samples from patients with APOE4, an allele associated with increased glial inflammation. We also examine the possibility that resveratrol reduces inflammation‐associated MMP release from cultured glia but spares neuronal activity‐dependent release from cultured cortical neurons. We observe that resveratrol decreases overall levels of MMP‐2 and MMP‐9 in CSF samples from AD patients. Resveratrol also reduces CSF levels of tissue inhibitor of metalloproteinases‐1 (TIMP‐1), glial‐derived protein that restricts long‐term potentiation of synaptic transmission, in individuals homozygous for APOE4. Consistent with these results, we observe that resveratrol reduces basal and lipopolysaccharide (LPS)‐stimulated MMP and TIMP‐1 release from cultured microglia and astrocytes. In contrast, however, resveratrol does not inhibit release of MMP‐9 from cortical neurons. Overall, these results are consistent with the possibility that while resveratrol reduces potentially maladaptive MMP and TIMP‐1 release from activated glia, neuroplasticity‐promoting MMP release from neurons is spared. In contrast, resveratrol reduces release of neurocan and brevican, extracellular matrix components that restrict neuroplasticity, from both neurons and glia. These data underscore the diversity of resveratrol's actions with respect to affected cell types and molecular targets and also suggest that further studies may be warranted to determine if its effects on glial MMP release could make it a useful adjunct for AD‐ and/or anti‐amyloid therapy‐related damage to the blood brain barrier.